Golimumab has been shown to reduce the level of reactive oxygen species which are closely related to C-reactive protein, TNF-alpha, and IL-1 and IL-6 expressions.10-12 There is no study in the literature that examines the effects of TNF-alpha receptor antagonist GLM on the experimental acute AP models. The gene discussed is IL6; the disease is alkaline phosphatase measurement.